The Enhanced Adhesion of Eosinophils Is Associated with Their Prolonged Viability and Pro-Proliferative Effect in Asthma by Januskevicius, Andrius et al.
  
 University of Groningen
The Enhanced Adhesion of Eosinophils Is Associated with Their Prolonged Viability and Pro-
Proliferative Effect in Asthma
Januskevicius, Andrius; Janulaityte, Ieva; Kalinauskaite-Zukauske, Virginija; Gosens,
Reinoud; Malakauskas, Kestutis
Published in:
Journal of Clinical Medicine
DOI:
10.3390/jcm8091274
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Januskevicius, A., Janulaityte, I., Kalinauskaite-Zukauske, V., Gosens, R., & Malakauskas, K. (2019). The
Enhanced Adhesion of Eosinophils Is Associated with Their Prolonged Viability and Pro-Proliferative Effect
in Asthma. Journal of Clinical Medicine, 8(9), [1274]. https://doi.org/10.3390/jcm8091274
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the





The Enhanced Adhesion of Eosinophils Is Associated
with Their Prolonged Viability and Pro-Proliferative
Effect in Asthma
Andrius Januskevicius 1,*, Ieva Janulaityte 1, Virginija Kalinauskaite-Zukauske 2,
Reinoud Gosens 3 and Kestutis Malakauskas 1,2
1 Laboratory of Pulmonology, Department of Pulmonology, Lithuanian University of Health Sciences,
LT-44307 Kaunas, Lithuania
2 Department of Pulmonology, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania
3 Department of Molecular Pharmacology, University of Groningen, 9713 AV Groningen, The Netherlands
* Correspondence: andrius.januskevicius@lsmuni.lt
Received: 29 July 2019; Accepted: 20 August 2019; Published: 22 August 2019


Abstract: Before eosinophils migrate into the bronchial lumen, they promote airway structural
changes after contact with pulmonary cells and extracellular matrix components. We aimed to
investigate the impact of eosinophil adhesion to their viability and pro-proliferative effect on airway
smooth muscle (ASM) cells and pulmonary fibroblasts during different asthma phenotypes. A total
of 39 individuals were included: 14 steroid-free non-severe allergic asthma (AA) patients, 10 severe
non-allergic eosinophilic asthma (SNEA) patients, and 15 healthy control subjects (HS). For AA
patients and HS groups, a bronchial allergen challenge with Dermatophagoides pteronysinnus was
performed. Individual combined cells cultures were prepared between isolated peripheral blood
eosinophils and ASM cells or pulmonary fibroblasts. Eosinophil adhesion was measured by evaluating
their peroxidase activity, cell viability was performed by annexin V and propidium iodide staining,
and proliferation by Alamar blue assay. We found that increased adhesion of eosinophils was
associated with prolonged viability (p < 0.05) and an enhanced pro-proliferative effect on ASM
cells and pulmonary fibroblasts in asthma (p < 0.05). However, eosinophils from SNEA patients
demonstrated higher viability and inhibition of pulmonary structural cell apoptosis, compared to
the AA group (p < 0.05), while their adhesive and pro-proliferative properties were similar. Finally,
in the AA group, in vivo allergen-activated eosinophils demonstrated a higher adhesion, viability,
and pro-proliferative effect on pulmonary structural cells compared to non-activated eosinophils
(p < 0.05).
Keywords: eosinophil; adhesion; viability; proliferation; airway smooth muscle cell; pulmonary
fibroblast; phenotype; asthma
1. Introduction
Chronic eosinophilic inflammation is a major factor in the development of airway remodeling
in asthma [1]. The contribution of various cytokine networks makes asthma pathophysiology
very complex, and these mechanisms vary between patients with different asthma phenotypes.
Eosinophils are a significant source of cytokines, chemokines, growth factors, and enzymes [2],
therefore, their increased infiltration into asthmatic lungs leads to the disturbance of normal lung
homeostasis [3].
Eosinophils develop from bone marrow progenitors under the control of a dedicated set
of transcription factors and the cytokines interleukin (IL)-3, IL-5, and granulocyte-macrophage
colony-stimulating factor (GM-CSF) [4]. Eosinophils’ half-life is between 3 to 24 h in peripheral
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blood [5], while being in the lungs prolongs their half-life up to 36 h [6]. Survivability-promoting
signals can be different. IL-5 is the most important and specific survival factor for eosinophils [7],
but important mediators also include GM-CSF and IL-3 [8], tumor necrosis factor-α [9], leptin [10],
and cluster of differentiation 40 engagement [11]. It is known that combined culturing with pulmonary
structural cells promotes eosinophils survival [12–15], however, the precise mechanisms remain
unknown. Integrins as transmembrane molecular mechanosensors may change their activation
states under asthmatic conditions and transduce the signal through the cytoskeleton, thus regulating
eosinophil activity and viability [16,17].
In addition to chronic inflammation, both allergic and non-allergic phenotypes of asthma
are characterized by structural changes in the lungs, which is called airway remodeling [18].
Airway remodeling in asthma includes epithelial changes, subepithelial and airway smooth muscle
(ASM) thickening, as well as bronchial neoangiogenesis that develops after repetitive cycles of tissue
injury and abnormal repair processes because of chronic inflammation [19]. Airway remodeling
develops mainly because of disturbed ASM cells and pulmonary fibroblast proliferation that determine
the increase in tissue mass due to enhanced cell numbers and the release of the extracellular matrix
(ECM) [20]. Studies demonstrate that direct interaction with eosinophils promotes pulmonary
fibroblasts and ASM cell proliferation [21–24]. Eosinophil-released mediators, such as transforming
growth factor β-1 and cysteinyl leukotrienes, are the main ASM cells, as well as being pulmonary
fibroblast proliferation- and differentiation-promoting factors [25,26]; however, more research is
needed to understand increased eosinophil activity or prolonged viability dominates in their
pro-proliferative effect.
Asthma severity correlates with peripheral blood and sputum eosinophils count [27]. However,
as major symptoms and airway structural changes between allergic and non-allergic asthma phenotypes
overlap, the pathways through which the disease develops and how eosinophils are involved in the
disease pathogenesis are different [28]. This highlights the hypothesis that further course of the disease
during different asthma phenotypes or during disease exacerbation can be predicted not only by
increased eosinophil count but also by their different biological properties.
We hypothesized that adhesion of eosinophils may determine their survivability properties and
further effect on pulmonary structural changes in asthma. Isolated blood eosinophils demonstrate the
biological role closely related to lung eosinophil functions because they are mainly activated in the bone
marrow under the maturation and in peripheral blood by inflammatory mediators [29,30]. Therefore,
our use of a combined cell culture model between blood eosinophils and pulmonary structural cells
allows for imitation of in vivo processes. We evaluated the effect of adhesion to pulmonary structural
cells on eosinophil viability and pro-proliferative effects for different asthma phenotypes. Moreover,
we investigated, in vivo, how a provoked acute allergic asthma episode after a bronchial allergen
challenge affects eosinophil activity.
2. Experimental Section
2.1. Ethics Statement
The study protocol was approved by the Regional Biomedical Research Ethics Committee
of the Lithuanian University of Health Sciences (BE-2-13). Each participant was informed about
the ongoing investigation and gave his/her written consent. Trial registration: ClinicalTrials.gov
Identifier NCT03388359.
2.2. Study Population
The study population consists of only newly recruited, not studied individuals.
The study included steroid-free allergic asthma (AA) patients, severe non-allergic eosinophilic
asthma (SNEA) patients with high doses of inhaled steroids, and healthy non-smoking subjects
(HS) who comprised the control group. The participants were men and women between the ages of
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18–50 years old who signed written informed consent. The patients were recruited from the Department
of Pulmonology at the Hospital of the Lithuanian University of Health Sciences Kaunas Clinics.
The AA group were newly-established and untreated non-severe patients, approved with
symptoms and medical history for at least a 12 month period, having a positive skin prick test to
Dermatophagoides pteronyssinus allergen and positive bronchial challenge with methacholine.
The SNEA group was a non-allergic phenotype, approved by negative skin prick tests, and with
asthma diagnosis for at least 1 year. Peripheral eosinophil counts were≥0.3× 109/L during the screening
visit or ≥0.15 × 109/L if there was a documented eosinophil count ≥0.3 × 109/L in the 12 month period
before the screening. A severe course of the disease was approved with at least 12 month treatment of
high doses of inhaled steroids combined with long-acting beta-agonist ± long-acting antimuscarinic
agent ± episodic use of oral corticosteroids.
The HS group was without allergic and other chronic respiratory diseases.
Exclusion criteria for all groups were clinically significant permanent allergy symptoms,
active airway infection 1 month prior the study, exacerbation ≤ 1 month prior to study, use of
oral steroids ≤ 1 month prior to study, and smoking.
2.3. Study Design
Initially, all study subjects underwent physical examination, spirometry, a methacholine challenge
test, and a skin prick test to verify the inclusion and exclusion criteria. If individuals matched the
criteria, they were informed about the requirements for participation and informed written consent
was obtained.
At the first visit of the study, peripheral blood was collected and measured for exhaled fractional
exhaled nitric oxide (FeNO). Isolated peripheral blood eosinophils were counted, assessed in their
viability, and immediately prepared in combined cell cultures with ASM cells and pulmonary fibroblasts.
Additionally, AA patients and HS after primary collection of peripheral blood underwent a bronchial
allergen challenge with D. pteronyssinus allergen.
The second visit was 24 h after a bronchial allergen challenge for subjects whom this test was
performed, and all procedures were repeated according to the first visit. The experimental study
design is represented in Figure 1.
Eosinophil count (<1.5 × 106/20 mL blood), viability (<98%), and purity (<96%) after their isolation
processes, as well as eosinophil adhesion intensity (equal to control value) was used as experimental
exclusion criteria for all investigated subjects. All data provided in the manuscript were from subjects
who passed these criteria.
We performed the unblinded type of experiments, as well-planned preparation before the
recruitment of each study subjects was required, and the whole experimental plan was performed in
the same week.
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Figure 1. Experimental study design. CBC—Complete blood count; SNEA—Severe non-allergic 
eosinophilic asthma; AA—Allergic asthma; HS—Healthy subjects; FeNO—Fractional exhaled nitric 
oxide; ASM—Airway smooth muscle. 
2.4. Lung Function Testing 
Pulmonary function was tested by using an ultrasonic spirometer (Ganshorn Medizin Electronic, 
Niederlauer, Germany). Baseline forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), 
and FEV1/FVC ratio were recorded as the highest of three reproducible measurements. The results were 
compared with the predicted values matched for age, body height, and sex according to the standard 
methodology. 
Airway responsiveness was assessed using inhaled methacholine via pressure dosimeter (ProvoX, 
Ganshorn Medizin Electronic, Niederlauer, Germany). Aerosolized methacholine was inhaled at 2 min 
intervals, starting with a 0.0101 mg methacholine dose, and increasing it by steps up to 0.121, 0.511, and 
1.31 mg of the total cumulative dose was achieved, or until a 20% decrease in FEV1 from the baseline. 
The bronchoconstriction effect of each dose of methacholine was expressed as a percentage of decrease 
in FEV1 from the baseline value. The provocative dose of methacholine causing a ≥20% fall in FEV1 
(PD20M) was calculated from the log dose-response curve by linear interpolation of two adjacent data 
points. 
2.5. Skin Prick Testing 
All patients were screened for allergy by the skin prick test using standardized allergen extracts 
(Stallergenes, S.A., France) for the following allergens: D. pteronyssinus, Dermatophagoides farinae, cat 
and dog dandruff, five mixed grass pollens, birch pollen, mugwort, Alternaria, Aspergillus, and 
Figure 1. Experimental study design. CBC—Complete blood count; SNEA—Severe non-allergic
eosinophilic asth a; AA—Allergic asthma; HS—Healthy subjects; FeNO—Fractional exhaled nitric
oxide; ASM—Airway smooth muscle.
2.4. Lung Function Testing
Pulmonary function was tested by using an ultrasonic spirometer (Ganshorn Medizin Electronic,
Niederlauer, Germany). Baseline forced expir tory volume in 1 s (FEV1), forced vital capacity (FVC),
and FEV1/FVC ratio were recorded as the highest of thre reproducible measurements. The results
were compared with th predicted values matched for age, body height, and sex according to th
stand rd methodology.
Airway responsiveness was assessed using inhaled methacholine via pressure dosimeter (ProvoX,
Ganshorn Medizin Electronic, Niederlauer, Germany). Aerosolized meth choline was inhal d at 2 min
intervals, starting with a 0.0101 mg methacholine dose, and increasing it by st ps up to 0.121, 0.511,
a d 1.31 mg of the tot l cumulative dose was achi ved, or until a 20% decrease in FEV1 from the
baseline. The br nchoconstriction effect of each dose of meth choline was expressed as a percentage of
decrease in FEV1 from th baselin value. The provocative dose of methacholine causi g a ≥20% fall in
FEV1 (PD20M) was calculated from the log dose-response curve by linear interpolation of two adjacent
data points.
2.5. Skin Prick Testing
All patients were screened for allergy by the skin prick test using standardized allergen extracts
(Stallergenes, S.A., France) for the following allergens: D. pteronyssinus, Dermatophagoides farinae, cat and
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dog dandruff, five mixed grass pollens, birch pollen, mugwort, Alternaria, Aspergillus, and Cladosporium.
Diluent (saline) was used for the negative control, and histamine hydrochloride (10 mg/mL) was used
for the positive control. Skin testing was read 15 min after application. The results of the skin prick test
were considered positive if the mean wheal diameter was higher than 3 mm.
2.6. FeNO Measurement
All study subjects underwent fractional exhaled nitric oxide (FeNO) analysis with an on-line
method using a single breath exhalation and an electrochemical assay (NIOX VERO, Circassia, UK),
according to European Respiratory Society—American Thoracic Society guidelines. Patients made an
inspiration of FeNO-free air via a mouthpiece, immediately followed by full exhalation at a constant
rate (50 mL/s) for at least 10 s. The mean of three readings at the end of the expiration (plateau phase)
was taken as the representative value for each measurement. Values that were 12 ppb or more were
considered elevated values, according to ATS-ERS criteria.
2.7. Bronchial Allergen Challenge Test
Inhaled D. Pteronyssinus allergen (DIATER, Spain) was delivered via pressure dosimeter (ProvoX,
Ganshorn Medizin Electronic, Niederlauer, Germany). The starting point for the assessment of
bronchoconstriction effect was 2 min after nebulized saline inhalation. The aerosolized allergen
was inhaled at 10 min intervals, starting with 0.1 histamine equivalent prick (HEP)/mL allergen
concentration, increasing it by steps up to 1.0, 10.0, 20.0, 40.0, 60.0 HEP/mL, or if a 20% decrease in FEV1
from the baseline was achieved. The provocative dose of allergen causing a ≥20% fall in FEV1 (PD20A)
was calculated from the log dose-response curve by linear interpolation of two adjacent data points.
2.8. Analysis of Peripheral Blood Cells
The peripheral blood analysis for the complete blood count test was performed on an automated
hematology analyzer XE-5000™ (Sysmex, Kobe, Japan).
2.9. Granulocyte Isolation from Human Peripheral Blood and Eosinophil Enrichment
Approximately 24 mL of peripheral blood was collected into sterile Ethylenediaminetetraacetic
acid-containing vacutainers (BD Bioscience, San Jose, CA, USA). The whole blood was then diluted
with 1x phosphate-buffered saline (PBS) (GIBCO, Paisley, UK) up to 50 mL and mixed thoroughly.
The whole blood was layered on Ficoll-Paque PLUS (GE Healthcare, Helsinki, Finland) and centrifuged
at 400× g force for 30 min at room temperature. The supernatant was removed and the bottom-most
layer comprising the granulocyte fraction of cells and erythrocytes was collected. Then, hypotonic lysis
of erythrocytes was performed. Into the tubes with cells, half volume of sterile water was added and
gently mixed for no longer than 10 s, immediately supplementing the mixture with an equal volume of
2x concentrated PBS and centrifuged at 300× g force for 10 min. The procedure was repeated until no
red blood cells were left. Then, cells were counted and viability evaluated using an ADAM automatic
cell counter (Witec AG, Switzerland). Eosinophil enrichment was performed by negative selection from
the granulocyte fraction using Magnetic-activated cell sorting (MACS)magnetically-labeled MicroBeads
(Miltenyi Biotec, Somerville, MA, USA). The manufacturer confirms that eosinophil separation kits
do not influence eosinophil viability, and that separation efficiency is more than 96%. MACS buffer
(containing 0.5% bovine serum albumin (BSA) and 2 mM EDTA in PBS, with a pH of 7.2) was prepared
by diluting MACS BSA stock solution 1:20 in autoMACS rinsing solution. The granulocyte pellet
was resuspended in cold MACS buffer (40 µL per 1 × 107 cells) and incubated with biotin antibody
cocktail (biotin-conjugated monoclonal antibodies against CD2, CD14, CD16, CD19, CD56, CD123,
and CD235a (glycophorin A)) (10 µL per 1 × 107 cells) for 10 min. After incubation, 20 µL of anti-biotin
microbeads (microbeads conjugated to monoclonal mouse anti-biotin immunoglobulin(Ig)-G1 per
1 × 107 cells were added, mixed, and incubated for an additional 15 min at 4 ◦C. An large separation
column (Miltenyi Biotec, USA) was prepared during this time by placing the column in the magnetic
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field of a MACS separator and washing it with 2 mL of MACS buffer. A pre-separation filter (30 µm;
Miltenyi Biotec) was rinsed with MACS buffer and placed on top of the column. The cells were then
applied to the pre-separation filter/LS column, and the magnetically labeled non-eosinophils were
retained on the column in the magnetic field of the separator while the unlabeled eosinophils passed
through the column. Cells were eluted with 5 mL of MACS buffer and centrifuged (300× g, 10 min,
4 ◦C), and the pellet was resuspended in 5 mL of PBS. Eosinophils were counted using an ADAM
automatic cell counter. To check eosinophil purity after magnetic separation, a diluted eosinophil
suspension was analyzed by flow cytometer FacsCalibur (BD, USA) according to forward and side
light scattering to determine whether there were any other cells in the suspension (Figure 2). As an
internal control, after usage of the new isolation kit, eosinophil purity was tested with alternative
May-Grunwald Giemsa staining and inspected by light microscopy.
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ASM and MRC-5 cells were grown in six-well (confluency approximately 16 × 104 cells) or 24-
well (confluency approximately 4 × 104 cells) culture plates (CytoOne, StarLab, Brussels, Belgium.). 
Co-cultures with isolated eosinophils were prepared by adding 5 × 104 or 1.25 × 104 of eosinophils, 
respectively. For observing and visualization of cell growth and co-cultures, we used an inverted 
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Figure 2. Eosinophil enrichment. (A) perip r l l od granulocytes after igh-density centrifugation
and erythrocyte lysis. (B) peripheral blood e sinoph ls after negativ magnetic labeling and separation.
Collected cell number—1 × 105. Eosinophil quantity expressed from total collected cells counts
rejecting debris.
2.10. Combined Cell Cult res between Isolated Eosi ils and ASM Cells or Pulmonary Fibroblasts
Individual combined cell cultures (co-cultures) of eosinophils and pulmonary structural cells
were prepared for all experiments. We used healthy human ASM cells, immortalized by stable
expression of human telomerase reverse transcriptase as described in [31] and a commercial MRC-5
(Sigma, Ronkonkoma, NY, USA) lung fibroblast line. The main cell line was cultivated under standard
culture conditions of 5% CO2 in air at 37 ◦C with medium renewal every 3 days. For all experiments,
passaged ASM cells were grown on plastic dishes in Dulbecco’s modified Eagle’s medium (DMEM)
(GIBCO by Life T chnologies, UK) and MRC-5 pulmonary fibroblasts in minimum essential Eagle’s
medium (EMEM) (GIBCO, Paisle , UK), supplemented with strepto ycin/penicillin (2% v/v; Pen-Strep,
GIBCO by Life Technologies, Paisley, UK), amphotericin B (1% v/v; GIBCO, Paisley, UK), and fetal
bovine serum (10% v/v; GIBCO by Life Technologies). After reaching sufficient confluence, cells were
passaged by trypsinization. Cells were serum-deprived in respective medium, supplemented with
antibiotics and insulin, transferrin, and selenium reagent (GIBCO by Life Technologies) before each
experiment to stop cell proliferation and avoid possible errors due to the effect of mediators in serum.
The same lines of ASM and MRC-5 cells were used for whole investigating subjects. Avoiding a
decrease in cell activity and viability after repeated times of passage, the new cells of the mainline
were unfrozen every time after six passages.
ASM and MRC-5 cells were grown in six-w ll (confluency approximately 16 × 104 cells) or
24-well (confluency approximately 4 × 104 cells) culture plates (Cyt One, StarLab, Brussels, Belgium.).
Co-cultures with isolated eosinophils were prepared by adding 5 × 104 or 1.25 × 104 of eosinophils,
respectively. For observing and visualization of cell growth and co-cultures, we used an inverted
microscope (CETI Inverso TC100, Medline Scientific, Chalgrove, UK) with a 10×/22 mm wide-field
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eyepiece and phase contrast 10×/0.25 objective and an installed XM10-IR-2 camera (Olympus, Tokyo,
Japan) (Figure 3).
At the study day, experiments were divided into different groups, according to the growth
medium supplements. Investigated individual blood serum—2% of v/v—was used to maintain further
eosinophil activation after isolation processes and to verify if the eosinophils were isolated in their
most activated form, whilst 25 nm of vitamin C (ascorbic acid) was used as the most accessible
natural antioxidant to eliminate eosinophil-released reactive oxygen species and verify its effect on the
proliferation of pulmonary structural cells.
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Figure 3. Combined cell cultures between eosinophils and ASM c lls. (A) the picture at 10× objective.
(B) the picture at 40× objective. (C) remaining eosinophil number after combined cell culture separation.
Collected cell number—1 × 105. Eosinophil number is expressed from total collected cell count,
rejecting cell debris.
2.11. Eosinophils Adhesion Assay
ASM or MRC-5 cells were seeded in 24-well plates and grown for 3 days in 5% CO2 at 37 ◦C until
a confluency of approximately 4 × 104 cells. Then, th medium was removed, and wells were washed
twice with warm PBS. The medium was changed 24 h before the experiments by adding serum-free
medium, supplemented with 1% insulin-transferrin-selenium reagent. Eosinophil adhesion was
measured after 1 h of incubation, which is a sufficient period for eosinophils to adhere in co-culture [22].
After incubation, non-adhered eosinophils were removed, and the remaining cells were washed twice
with warm PBS. Eosinophil adhesion was determined by measuring residual eosinophil peroxidase
(EPO) activity as described [32]. Because intercellular EPO levels were identified as being decreased in
eosinophils from asthmatic individuals owing to degranulation [33], we normalized it by preparing a
calibration curve of fixed eosinophil count EPO activity for each experiment. To assay EPO activity,
116 µL of DMEM medium without phenol red and 116 µL of EPO substrate (1 mM H2O2, 1 mM
o-phenylenediamine, and 0.1% Triton X-100 in Tris buffer, pH 8.0) were added to each well. After 30 min
at 37 ◦C, 68 µL of 4 M H2SO4 was added to each well to stop the reaction and the absorbance was
measured at 490 nm by a microplate reader. Results were expressed as % of adhered eosinophil
number from max added, calculated from a calibration curve. Added eosinophil number—1.25 × 104
(double amount—2.5 × 104).
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2.12. Cell Viability Assay
Viability of ASM cells, pulmonary fibroblasts, and eosinophils were performed by fluorescent
staining with annexin V for apoptotic cells and propidium iodide (PI) for necrotic cells.
ASM cells and pulmonary fibroblasts were grown in six-well plates until confluency of
approximately 16 × 104 cells. On the day of experiments, a co-culture with 5 × 104 of isolated
eosinophils was prepared in the serum-free growth medium, or medium supplemented with 2% (v/v)
of investigated subjects’ blood serum. After 24 h of co-culturing, used eosinophils were collected into
15mL centrifuge tubes (Corning Inc., New York, NY, USA), together with eosinophils incubated alone
at the same conditions. Then, ASM cells and pulmonary fibroblasts were trypsinized, collected and,
together with eosinophils, centrifuged at 400× g for 10 min.
For the cell viability assay, we used an fluorescein isothiocyanate (FITC) Annexin V Apoptosis
Detection Kit II (BD Bioscience, San Jose, CA, USA) and adapted the method according to the
manufacturer’s recommendation. Before every experiment, we used additional controls of unstained
cells, cells stained with FITC annexin V (no PI), and cells stained with PI (no FITC annexin V).
For the viability assay of structural cells as a control, we used ASM cells or pulmonary fibroblasts
without co-culturing with eosinophils. Eosinophil’s effect was compared with normal ASM and
pulmonary fibroblast apoptosis in the serum-free growth medium, but was supplemented with an
insulin-transferrin-selenium compound to maintain normal conditions.
For the viability assay of eosinophils, we normalized the data according to the results received
from the centrifuged growth medium, which was used in the control structural cell cultures without
co-culturing with eosinophils and excluding possible errors from cellular debris. Eosinophils and
structural cells significantly differ in size and granularity, therefore, appropriate gating on forward and
side scattering excludes any remaining culture heterogeneity.
2.13. Alamar Blue Proliferation Assay
Cells for proliferation measurements were grown in 24-well plates in conditions described
previously in fetal bovine serum-supplemented growth medium until confluency of approximately
4 × 104 cells/well. Growth medium was changed into the serum-free medium 24 h before the
experiments. ASM cells or pulmonary fibroblasts were co-cultured with a respective group of
eosinophils isolated from AA patients, SNEA patients, or the HS for 72 h. Thereafter, all cells were
washed twice with warm PBS, plates were gently smashed in the middle of the plate to detach residual
eosinophils who were significantly more weakly adhered compared with structural cells, and again
were washed twice with warm PBS. Proliferation was evaluated by incubating wells with Hank’s
balanced salt solution containing Alamar blue solution (10% v/v; Invitrogen by Life Technologies,
Paisley, UK). Conversion of Alamar blue to the reduced form was dependent on the metabolic
activity of structural cells and was assayed by dual-wavelength spectrophotometry at wavelengths
of 570 nm and 600 nm. As indicated by the manufacturer, the degree of Alamar blue conversion
is proportional to the number of viable cells. The data are expressed as the percent increase or
decrease in Alamar blue conversion by ASM cells or pulmonary fibroblasts compared with control cells
(without co-culturing with eosinophils), which did not proliferate during the culturing period because
serum-free growth medium were used. Added eosinophils number—1.25 × 104; 2x amount—2.5 × 104;
1/2x amount—0.6 × 104. Used investigated subjects blood serum volume—2% v/v; ascorbic acid
concentration—25 nM.
2.14. Statistical Analysis
Statistical analysis was performed with GraphPad Prism 6 for Windows (ver. 6.05, 2014;
GraphPad Software Inc., San Diego, CA, USA). Significant differences between two independent
groups were determined using the Mann–Whitney two-sided U-test. The Wilcoxon matched-pairs
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signed-rank two-sided test was used for dependent groups. Minimum limit for statistically significant
values—p < 0.05.
3. Results
3.1. Characteristics of the Studied Participants
We investigated 39 nonsmoking adults (14 men and 25 women): 14 steroid-free non-severe allergic
asthma (AA) patients, 10 severe non-allergic eosinophilic asthma (SNEA) patients, and 15 healthy
non-smoking control subjects (HS). The main characteristics of the study participants are shown in
Table 1. The highest eosinophils count was observed in the SNEA group, however, in AA patients,
it was also increased compared with HS. The IgE levels were significantly increased in AA and SNEA
patients, compared with HS, but the highest level was in the AA group. FeNO was equally increased in
both the AA and SNEA groups, compared with HS. Moreover, at the baseline, significant deterioration
of lung function was observed only in SNEA patients.
Table 1. Demographic and clinical characteristics of the study population.
Healthy Subjects SNEA Patients AA Patients
Number, n 15 10 14
Sex, M/F 3/12 4/6 7/7
Age, years 28.4 ± 1.8 46.5 ± 3.0 #,* 28.0 ± 2.3
BMI, kg/m2 23.2 ± 1.2 26.9 ± 2.2 24.7 ± 1.6
PD20M, geometric mean (range), mg NR ND 0.08 (0.02–0.26)
PD20A, geometric mean (range), HEP/mL NR ND 0.84 (0.15–3.04)
IgE, IU/mL 29.5 ± 6.0 147.2 ± 30.7 * 202.8 ± 41.9 *
FEV1, L 3.9 ± 0.18 2.0 ± 0.4 #,* 3.9 ± 0.2
FEV1, % of predicted 106.6 ± 3.7 57.6 ± 8.6 #,* 95.9 ± 3.3
Blood eosinophil count, ×109/L 0.18 ± 0.02 0.52 ± 0.11 #,* 0.36 ± 0.07 *
FeNO, ppb 12.9 ± 1.5 44.9 ± 10.7 * 59.5 ± 11.5 *
AA—Allergic asthma; SNEA—Severe non-allergic eosinophilic asthma; F—Female; M—Male;
FEV1—Forced expiratory volume in 1s; PD20M—The provocation dose of methacholine causing a 20%
decrease in FEV1; PD20A—the provocation dose of allergen D. pteronyssinus causing a 20% decrease in FEV1;
BMI—Body mass index; FeNO—Fractional exhaled nitric oxide; IgE—Immunoglobulin E; NR—Not responded;
ND—Not done. Data presented as the mean ± standard error of the mean, except PD20M and PD20A which are
provided as geometric mean (range). * p < 0.05 compared with HS group; # p < 0.05 compared with AA group.
Statistical analysis—Mann–Whitney two-sided U-test.
3.2. Eosinophil Adhesion and Survivability
We observed that 71.7% ± 3.5% of AA patients’ and 66.6% ± 5.8% of SNEA patients’ eosinophils
adhere onto the surface of ASM cells after 1 h of incubation, and this count was significantly increased
compared to healthy eosinophils (47.2% ± 3.7%, p < 0.05) (Figure 4A). Supplementing growth
medium with investigated individuals’ blood serum had a significant negative effect only in the
SNEA group—the adhered eosinophils ratio decreased to 46.7% ± 7.9% of the added eosinophils
count, p < 0.05. Moreover, by using double the amount of added eosinophils in the culture well,
we received a significant (p < 0.05) decrease in the adhered eosinophils ratio in the AA and SNEA
groups to 53.8% ± 5.0% and 50.5% ± 6.4% of the total added eosinophil count, respectively, with no
differences in the HS group (Figure 4A). Similar results were obtained by measuring AA and HS
eosinophil adhesion to pulmonary fibroblasts—adhered eosinophils’ number in the AA group was
61.2% ± 4.6%, and 37.3% ± 3.7% in the HS group, p < 0.05. Significant differences after supplementing
the medium with blood serum were not observed in both groups. Moreover, in the AA group,
the adhered eosinophil ratio decreased to 43.8% ± 7.4% after using double the amount of added
eosinophils (p < 0.05) (Figure 4B).
Moreover, we observed that AA and HS eosinophils’ peroxidase activity, evaluated as the
ability to oxidize o-phenylenediamine in the presence of their peroxidases, are similar—The average
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absolute value values of oxidized o-PD was 0.21 ± 0.04 optical density (O.D) and 0.2 ± 0.3 O.D,
respectively. The average SNEA eosinophil peroxidase activity was only 0.12 ± 0.02 O.D; however,
there was no statistical significance upon comparison with AA and HS groups, p = 0.069 and 0.073,
respectively (Figure 4C).
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smooth muscle (ASM) cells; (B) eosinophil adhesion in co-culture with pulmonary fibroblasts.
(C) Eosinophil peroxidase (EP ) substrate activity of 12,500 eosinophils. EOS—eosinophils,
AA—Allergic asthma, EA—S vere non-allergic eosinophilic asthma, HS—Healthy subjects.
Results from independent experiments of AA—n = 14; HS n = 15; SNEA—n = 10. * p < 0.05
compared with adhesion of the healthy eosinophil group. Added blood serum: 2% of V/V.
Statistical analysis: between investigated groups—Mann–Whitney two-sided U-test; within one
study group—Wilcoxon matched-pairs signed-rank two-sided test.
Furthermore, we investigated the eosinophil adhesion effect on their survivability. We observed
that 71.5% ± 1.1% of HS eosinophils are still viable after 24 h of incubation in serum-free growth
medium, and that this amount is significantly lower when compared with the viability of AA and
SNEA patients’ eosinophils at 74.6% ± 0.5% and 77.1 ± 0.5%, re pectively. The number of viable
eosinophils increased significantly to 82.3% ± 0.4% in the AA group and to 74.2% ± 0.5% in the
HS group when the medium was supplemented with 2% of v/v of the investigated subjects‘ blood
serum (p < 0.01), but it had no effect on the SNEA patient group. Making co-cultures with ASM
cells in serum-free medium had the same effe t as blood serum—In the AA group, the number of
viable eosinophils increased to 83.6% ± 0.4%; in the SNEA group, to 84.2% ± 0.4%; in the HS group,
to 75.1% ± 0.8% (p < 0.05), and this effect in AA and SNEA groups was significantly greater compared
with HS (p < 0.05). A similar effect was obtained when co-cultures of eosinophils were taken from
AA and HS groups with pulmonary fibroblasts–viability increased to 82.3% ± 0.4% and 73.0% ± 1.2%,
respectively, (p < 0.05). Supplementing co-culture growth medium with investigated subjects’ blood
serum did not have any additional effect on the viability of eosinophils (Figure 5).
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conditions. Results fro independ t experiments of AA—n = 14, HS—n = 15, SNEA—n = 10;
AA—Allergic asthma, SNEA—Severe non-allergic eosinophilic asthma, HS—Healthy subjects. * p < 0.05
compared with the viability of the healthy eosinophil group; # p < 0.05 compared with the viability of
the SNEA eosinophil group; Added blood serum—2% of v/v. Statistical analysis: between investigated
groups—Mann–Whitney two-sided U-test; within one study group—Wilcoxon matched-pairs
signed-rank two-sided test.
3.3. Eosinophil Effect on Pulmonary Structural Cell Proliferation and Apoptosis
After 72 h of co-culturing, eosinophils promoted ASM cell proliferation by 13.0% ± 2.4%
in AA and 9.3% ± 3.2% i SNEA, and the effect was significantly higher compared to the HS
group—proliferation increased by 4.0% ± 1.6% (p < 0.05). Supplementing growth medium with 2% of
investigated subjects’ lood serum had a positive effect on ASM cell proliferation. In the AA group,
proliferation increased by 23.8% ± 7.0% if ASM cells were cultured alone in serum-supplemented
medium and did not ignificantly different if th y were u tured in serum-supplemented medium
with eosinophils—proliferation increased by 27.2% ± 8.7%. The same results were received in the
SNEA group (proliferation increased by 34.3% ± 10.8% and 28.1% ± 10.4%, p < 0.05) and the HS group
(increased by 25.4% ± 5.7% and 30.8% ± 4.6%, p < 0.05). Moreover, supplementing serum-free growth
medium with 25 nM of ascorbic acid significantly decreased ASM proliferation by 36.3% ± 11.6% in
AA, 27.4% ± 17.6% in SNEA, and 22.3% ± 12.5% in the HS group. The combined cell culture with
eosinophils did not change the ascorbic acid effect on ASM cell proliferation in the AA and SNEA
groups (decreased by 33.9% ± 10.7% and 33.6% ± 14.8%, respectively) but removed its negative effect
in the HS group (Figure 6A).
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ASM cell proliferation; (B) eosinophils’ effect on pulmonary fibroblast proliferation; (C) the effect of
adding a different eosinophil count on ASM cell proliferation; (D) the effect of adding a different
eosinophil count on pulmonary fibroblast proliferation. Results from independent experiments of
AA—n = 14, HS—n = 15, SNEA—n = 10. * p < 0.05 compared with control ASM cells or pulmonary
fibroblasts without co-culturing with eosinophils, # p < 0.05 compared with the healthy subject group.
Added eosinophils count—1/2x = 6,250, 1x = 12,500, 2x = 25,000. Added blood serum—2% of v/v.
Ascorbic acid concentration—25 nM. Statistical analysis: between investigated groups—Mann–Whitney
two-sided U-test; within one study group—Wilcoxon matched-pairs signed-rank two-sided test.
We measured the AA and HS eosinophil effect on the proliferation of another structural cell
type—Pulmonary fibroblasts. We received imilar results—Proliferation significan ly increased
by 11.4% ± 2.3% in AA and 4.6% ± 1.6% in HS groups af er co-culturing with eosinophils.
Supplementing growth medium with blood serum also had a positive effect—The pulmonary fibroblast
cell number increased by 18.4%± 5.3% and 10.8%± 4% in the AA and HS groups, respectively. However,
co-culturing with eosinophils in serum-supplemented growth medium increased proliferation by
19.2% ± 4.1% in the AA group, but in the HS group, the effect of eosinophils was the same as in
serum-free medium. Different results, compared with co-cultures with ASM cells, were seen by
evaluating the effect of ascorbic acid on the proliferation of pulmonary fibroblasts. In the AA group,
fibroblasts did not lose their proliferative activity after supplementing growth medium with 25 nM of
ascorbic acid; however, a significant decrease (6.5% ± 2.6%) was observed when measuring the effect of
HS eosinophils on fibroblast proliferation in ascorbic acid-supplemented growth medium (Figure 6B).
Finally, we investigated how adding different quantities of eosinophils correlate with their effect
on structural cell proliferation. We determined that in the AA group, half (1/2x) the number of
eosinophils had a similar effect as a typically-used eosinophil number on ASM cell proliferation and
increased it by 13.02% ± 4.2%; however, after using twice (2x) the number of eosinophils, the significant
pro-proliferative effect was lost. By using pulmonary fibroblasts, the results were different—1/2x
and 2x quantity of eosinophils had no positive effect on cell proliferation. In the SNEA group,
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we used only co-cultures with ASM cells and observed that a 1/2x quantity of eosinophils had no
significant proliferative effect, but a 2x quantity increased ASM proliferation by 12.4% ± 5.2% (p < 0.05),
without significant differences to the effect of a typically-used eosinophil number. In the HS group,
we determined that a 1/2x quantity of eosinophils had no effect on ASM cells or pulmonary fibroblast
proliferation; however, for a 2x eosinophil quantity, both cases significantly decreased the eosinophil
proliferation by 8.5% ± 3.4% and 12.0% ± 5.5%, respectively (p < 0.05) (Figure 6C,D).
We investigated the mechanisms through which eosinophils affect pulmonary structural cell
proliferation. We measured the eosinophil effect on pulmonary structural cell apoptosis after 24 h of
co-culturing. Approximately 9.2% ± 0.6% of ASM cells and 7.5% ± 0.4% of pulmonary fibroblasts in
culture are apoptotic after culturing and detachment procedures. After co-culturing with eosinophils,
the apoptotic ASM cell number significantly (p < 0.05) decreased to 5.3% ± 0.5% in the AA patients
group, to 4.0 ± 0.3 in the SNEA patients group (p < 0.05 compared with AA), but had no significant
effect (p = 0.14) in the HS group. Co-culturing with eosinophils reduced the number of apoptotic
pulmonary fibroblasts in the AA patient group by 5.5% ± 0.4% (p < 0.05) but had no effect in the HS
group. Supplementing growth medium with blood serum (2% of v/v) of the investigated individuals
enhanced the effect of eosinophils, and the apoptotic ASM cell number decreased from 7.9% ± 0.9% in
serum-free medium to 4.9% ± 0.7% in serum-supplemented medium (p < 0.05). Unlike in the ASM
cells group, supplementing growth medium with blood serum enhanced the effect of eosinophils on
pulmonary fibroblasts only in the AA patients group—the apoptotic number reduced from 5.5% ± 0.4%
to 3.7%± 0.5% of the total cell count in culture. Moreover, considering that ascorbic acid is a well-known
antioxidant and can eliminate the effect of the released reactive oxygen species of eosinophils on ASM
cells or pulmonary fibroblast apoptosis, we supplemented the growth medium with a minimum of
25 nM of final concentration of ascorbic acid and obtained the result that the apoptotic ASM cell
number increased to 11.1% ± 0.9% in the AA group, to 12.3% ± 1.1% in the SNEA patient group, and
11.2% ± 1.1% in the HS group (p < 0.05), as well as the pulmonary fibroblast number to 13.0% ± 2.4%
in the AA patient group and 11.5% ± 1.0% in the HS group (p < 0.05) (Figure 7).
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SNEA—n = 10. * p < 0.05 compared with the healthy eosinophils group; # p < 0.05 compared with the 
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3.4. The Effect of Bronchial Allergen Challenge to Eosinophil Activity 
Figure 7. Eosinophils’ effect on pulmonary structural cell apoptosis. (A) Apoptosis of ASM cells;
(B) apoptosis of pulmonary fibroblasts. AA—Allergic asthma, SNEA—Severe non-allergic eosinophilic
asthma, HS—Healthy subjects. Results from independent experiments of AA—n = 14, HS—n = 15,
SNEA—n = 10. * p < 0.05 compared with the healthy eosinophils group; # p < 0.05 compared with
the SNEA eosinophils group. Added blood serum—2% of v/v; ascorbic acid concentration—25 nM.
Statistical analysis: between investigated groups—Mann–Whitney two-sided U-test; within one study
group—Wilcoxon matched-pairs signed-rank two-sided test.
3.4. The Effect of Bronchial Allergen Challenge to Eosinophil Activity
The bronchial challenge with D. pteronysinnus allergen was performed for 11 individuals from
the AA patient group and 11 individuals from the HS group. The effect of in vivo allergen provoked
J. Clin. Med. 2019, 8, 1274 14 of 23
disease exacerbation to eosinophil activity and was evaluated by comparing the results before and
24 h after a bronchial allergen challenge of the same study subject. A significant increase was
observed in the peripheral blood eosinophil count in the AA group following allergen exposure from
0.38 ± 0.08 × 109/L to 0.45 ± 0.06 × 109/L of cells, without significant changes in the HS group.
Eosinophil adhesion 24 h after a bronchial allergen challenge increased only in the AA group
with no effect on HS eosinophils. The number of adhered eosinophils in co-cultures with ASM cells
increased from 69.5% ± 5.4% to 87.06% ± 3.1% and in co-cultures with pulmonary fibroblasts from
59.4% ± 4.3% to 76.2% ± 4.2% of the total added eosinophil count (p < 0.05) (Figure 8).
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Figure 8. Bronchial allergen challenge effect on the efficiency of eosinophil adhesion. (A) Eosinophils
adhesion in co-culture with ASM cells; (B) eosinophils adhesion in co-culture with pulmonary
fibroblasts. Results from independent experi ents of A—n = 11, HS—n = 11; EOS—Eosinophils,
AA—Allergic asthma, HS— ealthy subjects. 0.05 compared with the adhesion of the healthy
eosinophil group. V1—Visit 1 (before bronchial allergen challenge); V2—Visit 2 (24 h after bronchial
allergen challenge). Statistical analysis: between investigated groups—Mann–Whitney two-sided
U-test; within one study group—Wilcoxon matched-pairs signed-rank two-sided test.
A bronchial allergen challenge activated osinophils in vivo and had a positive effect on AA patients
eosinophils viability—The number of non-viable eosinophils decreased by 7.6% ± 1.8% if eosinophils
were incubated alone or in serum-free growth medium (p < 0.005), but had no effect on healthy
eosinophils. However, by using in vivo allergen-activated eosinophils and serum-supplemented
growth medium, a positive effec was only obtain d in the HS group (no -viabl eosi ils number
decreased by 6.3% ± 1.8%, p < 0.01), but had no effect on the AA patient group compared with
non-activated eosinophils. Moreover, AA patients’ allergen-activated eosinophil viability was increased
if they were co-cultured with pulmonary structural cells in serum-free medium (non-viable eosinophils’
number decreased by 7.6% ± 2.7% in co-culture with ASM cells, and by 8.3% ± 2.1% in co-culture with
pulmonary fibroblasts, p < 0.01). Co-culturing in investigated subjects’ blood serum-supplemented
growth medium did not have any further effect on eosinophil viability (Figure 9).
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Figure 9. The bronchial allergen challenge effect on the number of non-viable eosinophils. Results from
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Moreover, we evaluated in vivo the effect of activated AA and HS eosinophils on structural cell
proliferation. We observed that eosinophils’ pro-proliferative effect on ASM cells after a bronchial
allergen challenge was enhanced by 11.6% ± 8.7% in the AA group and by 9.8% ± 4.1% in the HS
group, compared with the effect of non-activated eosinophils. An enhanced pro-proliferative effect on
pulmonary fibroblasts was only observed in the AA group (enhanced by 7.2% ± 2.5%), compared with
the effect of non-activated eosinophils (Figure 10).J. Clin. Med. 2019, 8, x FOR PEER REVIEW 16 of 23 
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Figure 10. Bronchial allergen challenge effect on pulmonary structural cell proliferation.
(A) The effect of a bronchial allergen challenge on eosinophil-promoted ASM cell proliferation;
(B) the effect of a bronchial allergen challenge on eosinophil-promoted pulmonary fibroblast
proliferation. Results from independent experiments of AA—n = 11, HS—n = 11; V1—Visit 1
(before the bronchial allergen challenge); V2—Visit 2 (24 h after the bronchial allergen challenge).
Statistical analysis: between investigated groups—Mann–Whitney two-sided U-test; within one study
group—Wilcoxon matched-pairs signed-rank two-sided test.
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Finally, a bronchial allergen challenge enhanced the effect of eosinophils on the reduction of ASM
cells and pulmonary fibroblast apoptosis. The apoptotic ASM cell number reduced from 5.5% ± 0.5%
of the total cell count in culture, to 4.2% ± 0.4% in the AA patient group, and from 7.7% ± 0.7% to
5.8% ± 0.3% in the HS group. Meanwhile, the number of apoptotic pulmonary fibroblasts reduced
from 5.3% ± 0.4% to 3.9% ± 0.4% in the AA patient group, and from 7.2% ± 1.3% to 4.7% ± 0.5%
in the HS group. After supplementing growth medium with the blood serum of the investigated
individuals—collected after the bronchial allergen challenge—the effect of eosinophils on the reduction
of apoptosis in pulmonary fibroblasts was only enhanced in the AA patients group—the apoptotic cell
number decreased from 3.7% ± 0.5% in serum-free medium to 1.8% ± 0.6% in serum-supplemented
medium (p < 0.05) (Figure 11).
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Figure 11. The effect of a bronchial allergen challenge on pulmonary structural cell apoptosis. (A) The
effect of a bronchial allergen challenge on eosinophil-induced ASM cell apoptosis. (B) The effect of
a bronchial allergen challenge on eosinophil-induced pulmonary fibroblast apoptosis. Results from
independent experiments of AA—n = 11, HS—n = 11; V1—Visit 1 (before the bronchial allergen
challenge); V2—Visit 2 (24 h after the bronchial allergen challenge). Added blood serum—2% of v/v;
ascorbic acid concentration—25 nM. Statistical analysis: between investigated groups—Mann–Whitney
two-sided U-test; within one study group—Wilcoxon matched-pairs signed-rank two-sided test.
4. Discussion
Increased eosinophil adhesion and prolonged viability in asthma could be the reason for the
increased eosinophil number in asthmatic lungs because of their delayed migration to the bronchial
lumen, which contributes to more intense development of airway remodeling. In this study, we found
that adhesion of eosinophils of AA and SNEA patients to ASM cells or pulmonary fibroblasts was
increased when compared to the HS group. Adhesion to pulmonary structural cells had a significant
effect on prolonging the viability of eosinophils in all the investigated groups; however, the highest
effect was observed in SNEA patients. Moreover, serum-activated eosinophils from AA and SNEA
patients demonstrated an enhanced pro-proliferative effect on pulmonary structural cells. Furthermore,
eosinophils from SNEA patients had a more pronounced effect on reducing apoptosis of ASM
cells and pulmonary fibroblasts, however, with a similar pro-proliferative effect when compared
with eosinophils from patients with AA. In the AA group, in vivo allergen-activated eosinophils
demonstrated higher adhesion, viability, and pro-proliferative effects on pulmonary structural cells
compared to non-activated eosinophils.
Airway eosinophilia is associated with more frequent exacerbations of asthma, which contributes
to the development of airway remodeling [34–36]. Eosinophil infiltration from the circulation into the
asthmatic airway depends on the activation sites of eosinophils, which leads to their arrest on activated
endothelium, extravasation into the airway wall, and migration through airway tissues into the airway
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lumen. Airway eosinophils demonstrate increased activity of two main eosinophils integrins—α4β1
and αMβ2 [37]; moreover, blood eosinophil integrins are found to be in a more-activated state
during asthma [38]. Previously, we demonstrated that increased expression of eosinophil integrins
in asthma leads to increased eosinophil adhesion and is associated with eosinophil-induced airway
remodeling [22,23]. In the current study, we showed that in the bloodstream of the HS, between 40%
and 50% of eosinophils exist, which could rapidly (within the hour) adhere onto other cell or ECM
proteins, while during asthmatic conditions, this number increases to 60–70%, with no significant
difference between AA and SNEA phenotypes (Figure 4A,B). Moreover, pre-activation of isolated
eosinophils with mediators found in blood serum does not affect their adhesion properties; on the
contrary, blood serum from SNEA patients reduced the maximum number of adhered eosinophils,
probably because of the use of inhaled steroids. It demonstrates that eosinophils do not lose their
activity during the isolation processes. Furthermore, eosinophil degranulation, assessed by EPO
activity, did not statistically differ between the investigated groups; however, the EPO activity of
eosinophils of SNEA patients is prone to decrease (Figure 4C).
Eosinophils adhere when their integrins recognize and connect to counter-receptors on other cells
or ligands in the ECM proteins. However, there is a limited number of these counter-receptors that
could restrict eosinophil adhesion. We showed that after increasing the number of more-adhesive
eosinophils from AA and SNEA patients in the co-cultures, the ratio of adhered eosinophils to total
added eosinophils significantly decreased and became the same as in the HS group (Figure 4A,B).
We assumed that the management of pulmonary structural cell adhesion molecules and ECM component
expression could play an important role by regulating eosinophil-induced airway structural changes.
Increased eosinophil adhesion intensity could be explained by increased expression of outer membrane
integrins [22] or by their different activation states [37,39]. Integrins exist in an inactive bent,
an intermediate-activity extended closed, and a high-activity extended open conformation, and in
that way modulate eosinophil adhesion and migration [40,41]. The severity of the disease or disease
exacerbation could affect eosinophil’s integrin expression and its activation states, contributing to
eosinophil’s further pro-inflammatory effect. However, it requires expanded investigation in a
background of different asthma phenotypes and allergen-induced eosinophil activation.
Eosinophil’s contribution to airway remodeling in asthma depends not only on its increased
infiltration, but on its survivability in airways as well, which prolongs the effect of eosinophils on
pulmonary structural cells. It was primarily described from several scientist teams, who revealed
the importance of direct contact with pulmonary structural cells to their survivability, probably via
signaling through GM-CSF and IL-1β [12–15]. Circulating eosinophils are contained in the mixture of
various mediators found in peripheral blood, which regulates eosinophils’ activation and survival.
We found that AA and SNEA patients‘ eosinophils are characterized by greater survival compared with
those of HS; moreover, the highest eosinophil viability was observed in the SNEA group (Figure 5).
As eosinophils were incubated in serum-free growth medium, this demonstrated that SNEA patients‘
eosinophils had the strongest cytokine-induced survivability signals in peripheral blood. If eosinophils
were incubated in investigated individual serum-supplemented medium, AA eosinophils’ survival
significantly increased and remained higher when compared with HS eosinophils. Blood serum
enhanced eosinophils viability, thus demonstrating the healing process of isolated eosinophils if they
are not pre-activated by mediators found in asthmatic blood serum. However, SNEA patients‘ blood
serum had no effect on eosinophils’ survival, probably due to fully-occupied survivability regulating
receptors after eosinophil activation in vivo, or medications present in the blood serum (Figure 5).
Activation of eosinophilopoietin receptors [42] may not be the only factors regulating eosinophil
viability. Adhesion through integrins can also be understood as a survival signal [43]. Incubation for
24 h with ASM cells or pulmonary fibroblasts significantly increased AA and SNEA patients’ eosinophil
viability, compared with eosinophils cultured alone, and the highest effect was observed in the SNEA
patient group. This highlights the importance of contact with the opposite cell or their released
extracellular matrix proteins on eosinophils’ viability. Moreover, eosinophils equally adhere to ASM
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cells and pulmonary fibroblasts without preference for one cell type (Figure 4). However, more detailed
research is needed to understand whether eosinophils adhere more to adhesion molecules on the
surface of structural cells, or to specific sites on ECM proteins, and how this determines eosinophils’
viability. Furthermore, a longer incubation period between eosinophils and structural cells should
be used to find out how long eosinophils can stay viable for with or without an external stimulus in
different asthma phenotypes.
Asthma-related airway remodeling mostly involves the airway epithelium, ASM, and extracellular
matrix components [44]. As the number of eosinophils in asthmatic airways is enhanced, their role
in disturbing local homeostasis is indisputable. It is known that ASM cells proliferate more during
asthma; however, there is only minimal research showing that eosinophils influence this process [21–23].
Likewise, there is lack of information regarding the effect of eosinophils on pulmonary fibroblast
proliferation [24], which could significantly contribute to ECM remodeling in asthma, as well as
how eosinophils of SNEA patients affect pulmonary structural cell proliferation. When eosinophils
migrate to the airways, the surrounding mediators might change, and further activation of eosinophils
mostly depends on their activation in peripheral blood or pre-activation by released mediators of
pulmonary structural cells. In the current study, we investigated the effect of eosinophils on ASM cells
or pulmonary fibroblast proliferation in the context of individuals’ blood serum that might maintain
the initial activation of eosinophils. Our results demonstrated that eosinophils, isolated from SNEA
patients, have the same effect on ASM cell proliferation as eosinophils isolated from AA patients.
Moreover, both ASM cells and pulmonary fibroblasts respond similarly to the pro-proliferative effect
of eosinophils (Figure 6A,B).
There are many mechanisms through which cell proliferation can be promoted [45]. One of the
mechanisms revealed in this study demonstrated that eosinophils significantly inhibit pulmonary
structural cell apoptosis in AA and SNEA groups, but not in HS (Figure 7A,B); however, the precise
mechanism is unknown. Blood serum is important for structural cell proliferation and had a higher
pro-proliferative effect compared with eosinophils in all the investigated groups. However, there is no
exact information regarding the concentrations of mediators in the surrounding ASM cells and the
pulmonary fibroblast environment in vivo, which could be different from those used in vitro. Apoptosis
measurements also demonstrated that blood serum does not enhance the effect of eosinophils on
reducing ASM cell apoptosis in the AA and SNEA groups, as these eosinophils did not lose their
primary activity in peripheral blood after 24 h of incubation. However, less-activated eosinophils in the
HS group were pre-activated by blood serum and demonstrated a more pronounced effect in reducing
structural cell apoptosis (Figure 7A).
Eosinophils release not only remodeling-related mediators [1] but could also be toxic to many
tissues because of released cytotoxic cationic proteins [46]. The best known and most accessible
antioxidant is ascorbic acid, in which the blood levels are linked to asthma pathogenesis and its
prevention [47,48]. A concentration of more than 100 nM ascorbic acid could be toxic to many cells
while demonstrating a lower proliferative effect [49]. We used a concentration of only 25 nM ascorbic
acid, avoiding possible changes in growth-medium pH levels. However, our data showed that
ascorbic acid alone significantly reduced ASM cells, but not pulmonary fibroblast proliferation, which
could be partially explained by the close interface between ascorbic acid and collagen synthesis [50].
In combination with eosinophils, a negative ascorbic acid effect on ASM cells was eliminated only
in the HS group, but was evidenced for pulmonary fibroblasts. Moreover, eosinophils in ascorbic
acid-supplemented medium significantly increased ASM cells and pulmonary fibroblast apoptosis
in all the investigated groups (Figure 6A,B). However, there is no clear explanation of these results
according to the literature data, and therefore more research should be done with different ascorbic
acid concentrations and cell densities in co-cultures.
Eosinophils have two sides to their biological role that could be partly explained by existing
distinct eosinophil phenotypes in peripheral blood and lung tissues [51] with different biological roles.
One phenotype is inflammation-related, another one has a greater effect on the remodeling processes.
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It shows that in the AA, SNEA, and HS groups there can exist different proportions of eosinophil
phenotypes; therefore, an increased or decreased number of eosinophils in co-cultures disbalance the
effect of the predominant phenotype effect (Figure 5C,D). In the AA group, a twofold reduced number
of eosinophils had the same proliferative effect on ASM cells, but the effect was lost to pulmonary
fibroblasts; however, a twofold increased number of eliminated eosinophils induced ASM cells and
pulmonary fibroblast proliferation, probably due to an increased effect of the inflammation-related
eosinophil phenotype. In the SNEA group, a reduced number of eosinophils had no effect on ASM
proliferation, while normal and increased numbers of eosinophils had a similar positive effect. In the
HS group, the reduced eosinophil number eliminated their effect on ASM cells and pulmonary
fibroblast proliferation; however, a twofold increase in the number of eosinophils significantly reduced
structural cell proliferation. Different ratios of eosinophil phenotypes in peripheral blood during
AA, SNEA, and HS could explain these findings. In the HS group, as there should be less of specific
disease-related signals for the attraction of homeostatic eosinophils, the predominant phenotype might
be more inflammation-related eosinophils, which started to dominate after an increase in their count.
With the SNEA group, the predominant phenotype was remodeling-related homeostatic eosinophils,
and their proliferative effect correlated with their count, whereas in AA, the ratio should have been
intermediate and increased the number of added eosinophils, eliminating the proliferation-promoting
effect. However, the number of inflammatory eosinophils was not enough to reduce this effect
(Figure 5C,D). Moreover, there is a lack of studies about different eosinophil phenotypes; therefore,
more data is needed to confirm these results.
Asthma is a heterogeneous disease with multiple possible targets in its pathogenesis. AA severity
is associated with the frequency of exacerbations after exposure to allergens that may contribute to the
development of airway remodeling [52]. We sought to find out the role of eosinophils during an acute
asthma episode, which is determined only by their quantitative differences or can be characterized
by significant changes in their activity. During an allergen attack, released alarmins promote Th2
cells to produce eosinophilopoetins that may affect the number and functions of eosinophils [53].
Allergen-induced late asthmatic responses are mainly described by an increased number of airway
inflammatory cells; however, the exact changes in eosinophil activity under allergen-induced disease
exacerbation are mostly unknown. Our team previously demonstrated that during allergen-induced
late-phase airway inflammation, peripheral blood eosinophils demonstrated further alterations of
their functional activity, manifested by enhanced spontaneous reactive oxygen species production,
increased chemotaxis, and diminished apoptosis in patients with AA [54]. Our findings show
that the exposure of allergens activates AA patients’ eosinophils in vivo, or they are released from
bone marrow in a more activated state. They demonstrated increased adhesion and survivability
properties and confirmed that after an acute episode, released eosinophils can survive in an asthmatic
airway for a longer period (Figures 7 and 8). Moreover, allergen exposure had an effect on HS
eosinophils, also promoting their viability, although subjects from the HS group were not sensitized
to D. pteronyssinus. We used one of the most common home dust mite allergens with which the
whole human population frequently comes into contact. It allowed us to assume that after a constant
natural exposure of D. pteronyssinus, a memory of this allergen develops. The reaction of organisms to
the high doses of inhaled concentrated allergen is too weak for bronchoconstriction; however, it is
enough to slightly stimulate type-2 inflammation and activate eosinophils. This is important for future
investigations, which should aim to understand possible AA development later in life.
More-enhanced eosinophil activity during allergen-induced asthma exacerbation required more
intense disease treatment. Allergen-activated eosinophils demonstrated a twofold increased effect
to ASM cells and pulmonary fibroblast proliferation via reduced apoptosis (Figures 9 and 10).
It demonstrates that asthma exacerbation is associated with more intense development of airway
remodeling via eosinophils’ pro-proliferative effect. Tang and colleagues discovered that recruitment
of eosinophils into asthmatic lungs during allergen-induced airway responses proceed via the
IL-25/IL-25R axis and IL-25 neutralization and may be a potential therapeutic target for the attenuation
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of allergen-induced asthmatic responses mediated by airway eosinophilia [55]. However, there exists
other well-known alarmins, such as IL-33 or thymic stromal lymphopoietin, that could also contribute
to the recruitment of eosinophils into asthmatic lungs. Our findings suggest that eosinophil adhesion is
important for their activity and effect on pulmonary structural cells; therefore, inhibiting their adhesion
properties, together with chemotaxis, could be an effective way of attenuating their negative role
during different asthma phenotypes and disease exacerbations.
5. Conclusions
Increased adhesion of eosinophils prolonged their viability, and might be related to enhancing their
pro-proliferative effect on ASM cells and pulmonary fibroblasts in asthma. Moreover, eosinophils from
SNEA patients demonstrated higher viability and inhibition of pulmonary structural cell apoptosis
compared to the AA group, while the adhesive properties and pro-proliferative effects were similar for
both. In the AA group, in vivo allergen-activated eosinophils presented enhanced adhesive properties,
viability, and a pro-proliferative effect on pulmonary structural cells compared to non-activated
eosinophils. These results could be important in the development of new therapeutic tools for the
suppression of eosinophil functions in asthma, focusing not only on eosinophils’ depletion but also on
their survivability.
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